Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Bellinda L. King-Kallimanis"'
Autor:
Christina Yap, Olalekan Lee Aiyegbusi, Emily Alger, Ethan Basch, Jill Bell, Vishal Bhatnagar, David Cella, Philip Collis, Amylou C. Dueck, Alexandra Gilbert, Ari Gnanasakthy, Alastair Greystoke, Aaron R. Hansen, Paul Kamudoni, Olga Kholmanskikh, Bellinda L. King-Kallimanis, Harlan Krumholz, Anna Minchom, Daniel O'Connor, Joan Petrie, Claire Piccinin, Khadija Rerhou Rantell, Saaeha Rauz, Ameeta Retzer, Steven Rizk, Lynne Wagner, Maxime Sasseville, Lesley K. Seymour, Harald A. Weber, Roger Wilson, Melanie Calvert, John Devin Peipert
Publikováno v:
EClinicalMedicine, Vol 76, Iss , Pp 102838- (2024)
Summary: Early phase clinical trials provide an initial evaluation of therapies’ risks and benefits to patients, including safety and tolerability, which typically relies on reporting outcomes by investigator and laboratory assessments. Use of pati
Externí odkaz:
https://doaj.org/article/67c77703c1de4dd99159ee45db094c8f
Autor:
Bellinda L. King-Kallimanis, PhD, Andrea Ferris, MBA, Lisa Dropkin, BA, Mariel Molina, BS, Lydia Redway, BA, David E. Gerber, MD, Tracey L. Grant, MS, Upal Basu Roy, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100575- (2023)
Introduction: The purpose of the informed consent form (ICF) is to outline the risks and benefits of an interventional clinical trial to potential participants. The aim of this study was to explore the feasibility of a short addendum to the ICF, summ
Externí odkaz:
https://doaj.org/article/eef9e7fd318843f9b76a9a9133843a9c
Autor:
Tendai M. Chihuri, MD, MPH, Upal Basu Roy, PhD, MPH, Amy Moore, PhD, Anne-Marie Baird, PhD, Tracey L. Grant, MS, Bellinda L. King-Kallimanis, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100549- (2023)
Introduction: Several studies have highlighted coronavirus disease 2019 (COVID-19)–related disruptions in treatment and care in people living with lung cancer. However, few studies have assessed patient-reported perspectives on treatment disruption
Externí odkaz:
https://doaj.org/article/b56972eec30b43f491c92d7b92dae471
Autor:
Claire Piccinin, Ethan Basch, Vishal Bhatnagar, Melanie Calvert, Alicyn Campbell, David Cella, Charles S Cleeland, Corneel Coens, Anne-Sophie Darlington, Amylou C Dueck, Mogens Groenvold, Ralf Herold, Bellinda L King-Kallimanis, Paul G Kluetz, Dagmara Kuliś, Daniel O'Connor, Kathy Oliver, Madeline Pe, Bryce B Reeve, Jaap C Reijneveld, Xin Shelley Wang, Andrew Bottomley
Publikováno v:
Piccinin, C, Basch, E, Bhatnagar, V, Calvert, M, Campbell, A, Cella, D, Cleeland, C S, Coens, C, Darlington, A-S, Dueck, A C, Groenvold, M, Herold, R, King-Kallimanis, B L, Kluetz, P G, Kuliś, D, O'Connor, D, Oliver, K, Pe, M, Reeve, B B, Reijneveld, J C, Wang, X S & Bottomley, A 2023, ' Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials : findings from an international, multidisciplinary working group ', Lancet Oncology, vol. 24, no. 2, pp. e86-e95 . https://doi.org/10.1016/S1470-2045(22)00654-4
The use of item libraries for patient-reported outcome (PRO) measurement in oncology allows for the customisation of PRO assessment to measure key health-related quality of life concepts of relevance to the target population and intervention. However
Autor:
Meena N. Murugappan, Bellinda L. King-Kallimanis, Vishal Bhatnagar, Bindu Kanapuru, Joel F. Farley, Randall D. Seifert, David D. Stenehjem, Ting-Yu Chen, Erica G. Horodniceanu, Paul G. Kluetz
Publikováno v:
Quality of Life Research.
Autor:
Bellinda L King-Kallimanis, Vishal Bhatnagar, Erica G Horodniceanu, Ting-Yu Chen, Paul G Kluetz
Publikováno v:
Clinical Trials. 19:267-273
Objective Although patient-reported symptoms and side effects are increasingly measured in cancer clinical trials, an appropriate assessment frequency has not yet been established. To determine whether differences in assessment frequency affect the a
Autor:
Erica G. Horodniceanu, Vishal Bhatnagar, Ting-Yu Chen, Julia A. Beaver, Paul G. Kluetz, Lyna Merzoug, Jennifer J Gao, Bellinda L King-Kallimanis, Mallorie H. Fiero
Publikováno v:
Value in Health. 25:566-570
Objectives Many trials conclude “no clinically meaningful detriment” to health-related quality of life (HRQL) or function between arms, even when notable differential toxicity is observed. Mean change from baseline analyses of function or HRQL ca
Autor:
Stacie Hudgens, Scottie Kern, Alexandra I. Barsdorf, Sally Cassells, Alison Rowe, Bellinda L. King-Kallimanis, Cheryl Coon, Geoff Low, Sonya Eremenco
Publikováno v:
Value in Health.
Autor:
Sundeep Agrawal, Anup K. Amatya, Harpreet Singh, Lijun Zhang, Mehrnoosh Hadadi, Vishal Bhatnagar, Amna Ibrahim, Paul G. Kluetz, Bellinda L. King-Kallimanis, Julia A. Beaver, Shenghui Tang, Yutao Gong, Michael Brave, Mitchell S. Anscher, Chana Weinstock, Jaleh Fallah, Elaine Chang, Laleh Amiri-Kordestani, Richard Pazdur, James X Xu, Dow-Chung Chi, Daniel L. Suzman, Jamie R. Brewer, Marc R. Theoret, Kirsten B. Goldberg
Publikováno v:
The Lancet Oncology. 22:1230-1239
Little is known about the benefit-risk profile of second-generation androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. We aimed to examine the efficacy and safety of second-generation androgen receptor
Autor:
Paul G. Kluetz, Pallavi S. Mishra-Kalyani, Vishal Bhatnagar, Rajeshwari Sridhara, Jessica K Roydhouse, Roee Gutman, Bellinda L King-Kallimanis
Publikováno v:
Value in Health. 24:822-829
Unblinded trials are common in oncology, but patient knowledge of treatment assignment may bias response to questionnaires. We sought to ascertain the extent of possible bias arising from patient knowledge of treatment assignment.This is a retrospect